Safety and Monitoring Update on Isotretinoin
Canadian Dermatology Today · 23.06.2026 · 35-39
DOI: 10.58931/cdt.2026.72165 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Dermatology Today, online erschienen am 23.06.2026. Verfasst von Vincent Richer.
Abstract (Originalsprache)
Canadian dermatologists frequently encounter fear and misconceptions of isotretinoin among patients and the general public. In contrast, few medications in dermatology have been as transformative: since its introduction, isotretinoin has dramatically changed the treatment of acne through its potential for providing long-term remission (Figure 1). Initial consultations in which isotretinoin is proposed are often lengthy and emotionally charged, with substantial discussion devoted to drug safety, treatment monitoring, and risk-mitigation strategies. This article provides an evidence-based update on select safety concerns surrounding isotretinoin, including well‑established and serious risks, concerns that have been confidently refuted, and some less common issues frequently raised by patients based on their own research.
Zitieren
APA
Richer, V. (2026). Safety and Monitoring Update on Isotretinoin. Canadian Dermatology Today, 35-39. https://doi.org/10.58931/cdt.2026.72165
Vancouver
Richer V. Safety and Monitoring Update on Isotretinoin. Canadian Dermatology Today. 2026:35-39. doi:10.58931/cdt.2026.72165
BibTeX
@article{Richer2026,
author = {Richer, Vincent},
title = {Safety and Monitoring Update on Isotretinoin},
journal = {Canadian Dermatology Today},
year = {2026},
pages = {35--39},
doi = {10.58931/cdt.2026.72165}
}
EUVIMED